AbbVie Inc. (ABBV)
Here's Why AbbVie (ABBV) is a Strong Value Stock
Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.
How Will Skyrizi and Rinvoq Shape AbbVie's Q1 Immunology Sales?
ABBV heads into Q1 earnings with Skyrizi and Rinvoq in focus as Humira declines, while growth from new indications and market share gains is under watch.
Will AbbVie's Oncology Drugs Aid Top Line in 2026?
ABBV's oncology lineup faces a 2026 sales dip despite rising contributions from newer drugs, as pricing pressure on Imbruvica weighs on growth.
AbbVie: Strong 2026 Outlook, Expect Dividend Increases
AbbVie remains well-positioned for long-term growth, despite recent share price consolidation and near-term geopolitical headwinds. I expect Skyrizi and Rinvoq to drive double-digit revenue growth in 2026 and ahead of the company's initial guidance. With Humira erosion largely in the rearview mirror, I anticipate accelerating dividend increases and increased business development activity as the previous acquisitions are digested.
Investors Heavily Search AbbVie Inc. (ABBV): Here is What You Need to Know
Recently, Zacks.com users have been paying close attention to AbbVie (ABBV). This makes it worthwhile to examine what the stock has in store.
AbbVie (ABBV) Declines More Than Market: Some Information for Investors
AbbVie (ABBV) reached $206.23 at the closing of the latest trading day, reflecting a -1.01% change compared to its last close.
ABBV Stock Slides 5%: Is J&J's Icotyde a Threat to Skyrizi?
AbbVie stock sinks 5% as J&J's newly approved Icotyde raises competitive concerns for blockbuster Skyrizi in the fast-growing IL-23 market.
Buy Or Fear AbbVie Stock At $210?
AbbVie stock (NYSE: ABBV) experienced a 5% decline yesterday, and the reason is evident: the U.S. FDA has just approved Johnson & Johnson's Icotyde, the first oral IL-23 inhibitor on the market. This poses a significant threat because a daily pill presents a far more convenient option compared to AbbVie's injectable blockbuster, Skyrizi—the main growth driver AbbVie has depended on to counteract the Humira patent expiration.
AbbVie Slips Below 50-Day SMA: Buy, Sell or Hold the Stock?
AbbVie ABBV stock slipped below its 50-day simple moving average (SMA) on March 13, after consistently trading above it since mid-Feb. However, the stock has remained comfortably above its 200-day SMA for more than six months.
Here's Why AbbVie (ABBV) is a Strong Value Stock
Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.
AbbVie Inc. $ABBV Position Raised by Brown Brothers Harriman & Co.
Brown Brothers Harriman and Co. raised its position in shares of AbbVie Inc. (NYSE: ABBV) by 4.4% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 90,866 shares of the company's stock after purchasing an additional 3,867 shares during the period. Brown
Glenmede Investment Management LP Has $78.78 Million Stock Holdings in AbbVie Inc. $ABBV
Glenmede Investment Management LP trimmed its stake in shares of AbbVie Inc. (NYSE: ABBV) by 4.4% in the undefined quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 340,243 shares of the company's stock after selling 15,663 shares during the period.
